Ostarine MK2866 12.5MG
Day UK delivery
Days international delivery
MK2886 is a chemical currently being studied in Phase 1 & 2 Clinical Trials involving androgen therapy and other uses.
This product is not a food supplement, and under no circumstances is for human consumption.
Pellets are designed enable easy integration into laboratory experiments. Click here for more information
Please read our disclaimer for more information
Product name: MK2866
Synonyms: Ostarine, enobosarm, GTx 024
CAS : 841205-47-8
Molecular Formula: C19H14F3N3O3
Half-life: 24 hours
Appearance/color: White fine powder
Molecular Weight: 528.662 g/mol
Our products have a HPLC tested purity of ≥98.0%
You can request a copy of the HPLC reports by contacting us
Our manufacturer complies to the following:
- ISO 9001
- CQC China
Information below is provided to provide a general and fundamental view of this chemical, references to human use to correlate with data gathered within lab environments. Under no circumstances should you attempt to mimic this data.
What is Ostarine MK2866?
Ostarine was the name given to the compound MK-2866. This is a Selective Androgen Recepector Inhibitor, otherwise known as a SARM.
Pharmaceutical research and development company GTx were primary developers of this compound, and it’s intention was to treat or manage diseases such as Muscular Dystrophy (MS), HIV/AIDS and potentially be used in the treatment of Sarcopenia.
SARMS are a group of compounds which act upon androgen receptors within the body to cause anabolic effects, similar to Selective Estrogen Receptor Modulators (SERMS) such as Tamoxifen which is used primarily in the treatment of breast cancer.
Ostarine MK2866 and it's use in Chemistry
In recent years Ostarine has become popular with bodybuilders, and has been cited as a alternative to Anabolic Steroids.
The primary reason for this, is the fact that that Ostarine MK2866 has a potent anabolic effect, while having a very low androgenic effect. This allows users to experience less androgenic side effects while using these compounds.
Some androgenic activity may still exist, however, anecdotally, most users report very little if any androgenic side effects.
Vitro trials of Anabolism and Ostarine (MK2866)
In comparison to AAS, many consider Ostarine to be similar to the effects of Oxyandralone (Anavar). The primary characteristics of Anavar include lean muscle gain, no aromatisation (conversion to oestrogen), making Ostarine an ideal candidate for studies involving low estrogen/progesterone environments.
Ostarine SARM Adipose tissue lab studies
There have been various studies on the role of androgens in adipose tissue in mammals. The general consensus is that higher levels of androgens often result in a more positive disposition to a higher Fat Free Mass composition.
Both SARMS and AAS have a small effect directly on adipose tissue. Many studies have found that men with higher levels of AAS generally have leaner body compositions in mammals.
Theoretical HPTA Supression and Female Mammal use of the SARM Ostarine MK2866
All SARMS are capable of causing suppressing the HPTA, in lab studies. To a much lesser degree then hormones such as Testosterone and Trenbolone. Many researchers note that recovery from a Ostarine or other SARM treatment is much easier than recovering from the use of AAS.
One critical issue of Androgen Therapy in mammal treatment, is the female effects of androgens causing unwanted effects.
Ostarine SARM MK2866 Conclusions
Ostarine is a promising compound in the further studies of Androgens and SARMs in vitro/Vivo research.
The search for anabolic compounds for future medical use has become of great relevance, due to the negative implications of current androgen therapies. The use of common treatments are not selective, and can cause side effects of which some may be irreversible. There are an array of compounds currently under investigation, such as Andarine S4
Aside from androgen therapy, the use of Ostarine in the treatment of age related disorders may be another on label use of this compound. For conditions such as Osteoporosis.
Ostarine SARM Mechanism
The underlying chemistry behind Ostarine (and every other SARM, for that matter) is rather unique.
The chemical compounds found in this drug are literally engineered by scientists to specifically bind to androgen receptors inside the body (almost immediately after they have been absorbed), but unlike traditional anabolic steroid these compounds will not convert DHT into estrogen.
With Ostarine you’ll see much lower levels of estrogen produced alongside higher levels of testosterone, a big piece of the puzzle for those are looking to control their hormonal much more efficiently.
Ostarine is able to bind to androgen receptors without increasing estrogen levels through a unique method of protein synthesis. Not only are protein synthesis levels dramatically elevated with routine exposure to this chemical compound, but nitrogen retention is also dramatically increased as well.
Both of these factors are core environmental issues necessary for the that are looking to increase muscle tissue. Without improved protein synthesis and extra nitrogen retention of the body will not ramp up the production of new protein strands, and no new muscle tissue will be created along the way.
Interestingly enough, because of the unique chemical composition of this drug it has one of the shorter half-lives of any of the new SARMs produced in just the last 15 years or so. Manufacturers have been trying to find ways to stretch out this half-life, though no major ground has been broken on this endeavor over the past 10 years or so.
SARMs (as a general rule) are significantly safer to use than traditional anabolic steroid, if only because they do not mess with hormone levels quite as much. As highlighted earlier, estrogen levels aren’t going to be elevated alongside elevated testosterone level with Ostarine.
Water retention, bloating, gynecomastia, acne, hair loss, liver toxicity, or high blood pressure associated with the Ostarine chemical compounds. These are some of the more common side effects seen when estrogen levels are increased exponentially.
The first few SARMs were pioneered in the early 1940s, but new “designer drugs” like Ostarine have only been around for about a decade or so. This particular drug was produced in 2009, and while it doesn’t have the same track record or history as some of the other SARMs that have been produced for decades a number of clinical trials have been able to conclusively prove that it is effective and safe.
Research does suggest that HPTA suppression is going to occur with long-term exposure to Ostarine, and estradiol levels are also going to increase. More time and research will be necessary to fully understand what the potential long-term side effects and impacts could be from these changes to the body, but Ostarine hasn’t been around long enough to reach any definitive conclusions quite yet.